Literature DB >> 31686731

Genotyping and Frequency of PCSK9 Variations Among Hypercholesterolemic and Diabetic Subjects.

Edem Nuglozeh1,2, Mohammad Feroze Fazaludeen3, Nabil Hasona1,4, Tarja Malm3, Luisito B Mayor5, Awdah Al-Hazmi1, Ibraheem Ashankyty5.   

Abstract

Non-synonymous single-nucleotide polymorphism (SNPs) in the gene for proprotein convertase subtilisin/kexin type 9 (PCSK9) can influence cholesterol and glucose metabolism, leading to increased risk of cardiovascular disease and diabetes. To determine the frequency of four common PCSK9 SNPs, L10Ins, A56V, I474V, and E670G, in a population sample (n = 98) of the Hail region of Kingdom of Saudi Arabia. Blood was collected from participants; serum cholesterol, blood glucose and glycated hemoglobin were determined; genomic DNA was extracted and PCR amplicons from SNP-containing PCSK9 exons were subjected to Sanger sequencing. Out of 98 participants. 10 (10.20%) carried none of the SNPs, 2 (2.04%) the L10ins/A56V linked SNPs, 35 (35.71%) the I474V SNP, 22 (22.45%) both the I474V and E670G SNPs, and 29 (29.59%) the E670G SNP. Of the 30 eucholesterolemic diabetics patients, 11 (36.66%) carried the I474V SNP, 10 (33.33%) the E679G SNP and 6 (20%) the I474V/E679G. SNPs. Of 63 diabetic patients, 26 (41.26%) carry I474V SNP and 22 (34.92%) carry E670G SNP. Our data demonstrated that the I474V and E670G PCSK9 variants are very frequent in the Hail region of Saudi Arabia and are found at even higher frequency among diabetics. Further investigations are needed to determine whether these variations or another variant segregating with them can explain its apparent association with diabetes in this population. © Association of Clinical Biochemists of India 2018.

Entities:  

Keywords:  Diabetes; Eucholesterolemia; Hypercholesterolemia; PCSK9; Single-nucleotide polymorphism

Year:  2018        PMID: 31686731      PMCID: PMC6801243          DOI: 10.1007/s12291-018-0763-9

Source DB:  PubMed          Journal:  Indian J Clin Biochem        ISSN: 0970-1915


  23 in total

1.  Low density lipoprotein binding and uptake by human and rat islet beta cells.

Authors:  A Y Grupping; M Cnop; C F Van Schravendijk; J C Hannaert; T J Van Berkel; D G Pipeleers
Journal:  Endocrinology       Date:  1997-10       Impact factor: 4.736

2.  Genetic variants in PCSK9 in the Japanese population: rare genetic variants in PCSK9 might collectively contribute to plasma LDL cholesterol levels in the general population.

Authors:  Yasuko Miyake; Rina Kimura; Yoshihiro Kokubo; Akira Okayama; Hitonobu Tomoike; Taku Yamamura; Toshiyuki Miyata
Journal:  Atherosclerosis       Date:  2007-02-21       Impact factor: 5.162

3.  Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.

Authors:  Jonathan C Cohen; Eric Boerwinkle; Thomas H Mosley; Helen H Hobbs
Journal:  N Engl J Med       Date:  2006-03-23       Impact factor: 91.245

4.  Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population.

Authors:  Qin Cui; Xianxia Ju; Tao Yang; Mei Zhang; Wei Tang; Qi Chen; Yong Hu; Joseph V Haas; Jason S Troutt; Richard T Pickard; Ryan Darling; Robert J Konrad; Hongwen Zhou; Guoqing Cao
Journal:  Atherosclerosis       Date:  2010-10-30       Impact factor: 5.162

5.  Mutation in the PCSK9 Gene in Omani Arab Subjects with Autosomal Dominant Hypercholesterolemia and its Effect on PCSK9 Protein Structure.

Authors:  Khalid Al-Waili; Ward Al-Muna Al-Zidi; Abdul Rahim Al-Abri; Khalid Al-Rasadi; Hilal Ali Al-Sabti; Karna Shah; Abdullah Al-Futaisi; Ibrahim Al-Zakwani; Yajnavalka Banerjee
Journal:  Oman Med J       Date:  2013-01

6.  Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.

Authors:  Marianne Abifadel; Mathilde Varret; Jean-Pierre Rabès; Delphine Allard; Khadija Ouguerram; Martine Devillers; Corinne Cruaud; Suzanne Benjannet; Louise Wickham; Danièle Erlich; Aurélie Derré; Ludovic Villéger; Michel Farnier; Isabel Beucler; Eric Bruckert; Jean Chambaz; Bernard Chanu; Jean-Michel Lecerf; Gerald Luc; Philippe Moulin; Jean Weissenbach; Annick Prat; Michel Krempf; Claudine Junien; Nabil G Seidah; Catherine Boileau
Journal:  Nat Genet       Date:  2003-06       Impact factor: 38.330

7.  Low- and high-density lipoproteins modulate function, apoptosis, and proliferation of primary human and murine pancreatic beta-cells.

Authors:  Sabine Rütti; Jan A Ehses; Rahel A Sibler; Richard Prazak; Lucia Rohrer; Spiros Georgopoulos; Daniel T Meier; Nadja Niclauss; Thierry Berney; Marc Y Donath; Arnold von Eckardstein
Journal:  Endocrinology       Date:  2009-07-23       Impact factor: 4.736

8.  Genetic and metabolic determinants of plasma PCSK9 levels.

Authors:  Susan G Lakoski; Thomas A Lagace; Jonathan C Cohen; Jay D Horton; Helen H Hobbs
Journal:  J Clin Endocrinol Metab       Date:  2009-04-07       Impact factor: 5.958

Review 9.  PCSK9: a key modulator of cardiovascular health.

Authors:  Nabil G Seidah; Zuhier Awan; Michel Chrétien; Majambu Mbikay
Journal:  Circ Res       Date:  2014-03-14       Impact factor: 17.367

10.  Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes.

Authors:  Brian A Ference; Jennifer G Robinson; Robert D Brook; Alberico L Catapano; M John Chapman; David R Neff; Szilard Voros; Robert P Giugliano; George Davey Smith; Sergio Fazio; Marc S Sabatine
Journal:  N Engl J Med       Date:  2016-12-01       Impact factor: 91.245

View more
  1 in total

Review 1.  Single-nucleotide polymorphisms as important risk factors of diabetes among Middle East population.

Authors:  Iman Akhlaghipour; Amir Reza Bina; Mohammad Reza Mogharrabi; Ali Fanoodi; Amir Reza Ebrahimian; Soroush Khojasteh Kaffash; Atefeh Babazadeh Baghan; Mohammad Erfan Khorashadizadeh; Negin Taghehchian; Meysam Moghbeli
Journal:  Hum Genomics       Date:  2022-04-02       Impact factor: 4.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.